Darren Zhi Liang Mok

Mr. Darren Zhi Liang Mok

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2015 in BMC Developmental Biology
Verified
Journal Article
Open access
PDF file
DMDarren Zhi Liang Mok
Darren Zhi Liang Mok
PSPaul W. Sternberg
Paul W. Sternberg
TITakao Inoue
Takao Inoue
During the fourth larval (L4) stage, vulval cells of C. elegans undergo extensive morphogenesis accompanied by changes in gene expression. This phase of vulval development, occurring after the well-studied induction of vulval cells, is not well understood but is potentially a useful context in which to study how a complex temporal sequence of events is regulated during development. However, a system for precisely describing different phases of vulval development in the L4 stage has been lacking. We defined ten sub-stages of L4 based on morphological criteria as observed using Nomarski microscopy (L4.0 ~ L4.9). Precise timing of each sub-stage at 20 °C was determined. We also re-examined the timing of expression for several gene expression markers, and correlated the sub-stages with the timing of other developmental events in the vulva and the uterus. This scheme allows the developmental timing of an L4 individual to be determined at approximately one-hour resolution without the need to resort to time course experiments. These well-defined developmental stages will enable more precise description of gene expression and other developmental events.

19 September 2016 in Nature Microbiology
Verified
Journal Article
Closed access
KCKuan Rong Chan
Kuan Rong Chan
XWXiaohui Wang
Xiaohui Wang
WSWilfried Saron
Wilfried Saron
EGEsther Shuyi Gan
Esther Shuyi Gan
HTHwee Cheng Tan
Hwee Cheng Tan
EOEng Eong Ooi
Eng Eong Ooi

8 May 2020 in Viruses
Verified
Journal Article
Open access
PDF file
DMDarren Zhi Liang Mok
Darren Zhi Liang Mok
KCKuan Rong Chan
Kuan Rong Chan
Live-attenuated vaccines (LAVs) have achieved remarkable successes in controlling virus spread, as well as for other applications such as cancer immunotherapy. However, with rapid increases in international travel, globalization, geographic spread of viral vectors, and widespread use of vaccines, there is an increasing need to consider how pre-exposure to viruses which share similar antigenic regions can impact vaccine efficacy. Pre-existing antibodies, derived from either from maternal–fetal transmission, or by previous infection or vaccination, have been demonstrated to interfere with vaccine immunogenicity of measles, adenovirus, and influenza LAVs. Immune interference of LAVs can be caused by the formation of virus–antibody complexes that neutralize virus infection in antigen-presenting cells, or by the cross-linking of the B-cell receptor with the inhibitory receptor, FcγRIIB. On the other hand, pre-existing antibodies can augment flaviviral LAV efficacy such as that of dengue and yellow fever virus, especially when pre-existing antibodies are present at sub-neutralizing levels. The increased vaccine immunogenicity can be facilitated by antibody-dependent enhancement of virus infection, enhancing virus uptake in antigen-presenting cells, and robust induction of innate immune responses that promote vaccine immunogenicity. This review examines the literature on this topic and examines the circumstances where pre-existing antibodies can inhibit or enhance LAV efficacy. A better knowledge of the underlying mechanisms involved could allow us to better manage immunization in seropositive individuals and even identify possibilities that could allow us to exploit pre-existing antibodies to boost vaccine-induced responses for improved vaccine efficacy.

1 December 2021 in Cell Reports
Verified
Journal Article
Open access
CYClement Yau
Clement Yau
JLJohn Z.H. Low
John Z.H. Low
EGEsther S. Gan
Esther S. Gan
SKSwee Sen Kwek
Swee Sen Kwek
LCLiang Cui
Liang Cui
EOEng Eong Ooi
Eng Eong Ooi
Zika virus (ZIKV) is an Aedes-mosquito-borne flavivirus that causes debilitating congenital and developmental disorders. Improved understanding of ZIKV pathogenesis could assist efforts to fill the therapeutic and vaccine gap. We use several ZIKV strains, including a pair differing by a single phenylalanine-to-leucine substitution (M-F37L) in the membrane (M) protein, coupled with unbiased genomics to demarcate the border between attenuated and pathogenic infection. We identify infection-induced metabolic dysregulation as a minimal set of host alterations that differentiates attenuated from pathogenic ZIKV strains. Glycolytic rewiring results in impaired oxidative phosphorylation and mitochondrial dysfunction that trigger inflammation and apoptosis in pathogenic but not attenuated ZIKV strains. Critically, pyruvate supplementation prevents cell death, in vitro, and rescues fetal development in ZIKV-infected dams. Our findings thus demonstrate dysregulated metabolism as an underpinning of ZIKV pathogenicity and raise the potential of pyruvate supplementation in expectant women as a prophylaxis against congenital Zika syndrome.

24 August 2015 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Open access
KCKuan Rong Chan
Kuan Rong Chan
EZEugenia Ong Ziying
Eugenia Ong Ziying
DMDarren Zhi Liang Mok
Darren Zhi Liang Mok
EOEng Eong Ooi
Eng Eong Ooi
The lack of vaccines against several important viral diseases necessitates the development of therapeutics to save lives and control epidemics. In recent years, therapeutic antibodies have received considerable attention due to their good safety profiles and clinical success when used against viruses such as respiratory syncytial virus, Ebola virus and Hendra virus. The binding affinity of these antibodies can directly impact their therapeutic efficacy. However, we and others have also demonstrated that the subtype of Fc-gamma receptors (FcγRs) engaged influences the stoichiometric requirement for virus neutralization. Hence, the development of therapeutic antibodies against infectious diseases should consider the FcγRs engaged and Fc-effector functions involved. This review highlights the current state of knowledge about FcγRs and FcγR effector functions involved in virus neutralization, with emphasis on factors that can affect FcγR engagement. A better understanding of Fc-FcγR interactions during virus ...

30 October 2020 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
DMDarren Zhi Liang Mok
Darren Zhi Liang Mok
CCCandice Yuen Yue Chan
Candice Yuen Yue Chan
EOEng Eong Ooi
Eng Eong Ooi
KCKuan Rong Chan
Kuan Rong Chan
The ongoing coronavirus disease 2019 (COVID‐19) crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has triggered a large‐scale pandemic that is afflicting millions of individuals in over 200 countries. The clinical spectrum caused by SARS‐CoV‐2 infections can range from asymptomatic infection to mild undifferentiated febrile illness to severe respiratory disease with multiple complications. Elderly patients (aged 60 and above) with comorbidities such as cardiovascular diseases and diabetes mellitus appear to be at highest risk of a severe disease outcome. To protect against pulmonary immunopathology caused by SARS‐CoV‐2 infection, the host primarily depends on two distinct defense strategies: resistance and disease tolerance. Resistance is the ability of the host to suppress and eliminate incoming viruses. By contrast, disease tolerance refers to host responses that promote host health regardless of their impact on viral replication. Disruption of either resistance or disease tolerance mechanisms or both could underpin predisposition to elevated risk of severe disease during viral infection. Aging can disrupt host resistance and disease tolerance by compromising immune functions, weakening of the unfolded protein response, progressive mitochondrial dysfunction, and altering metabolic processes. A comprehensive understanding of the molecular mechanisms underlying declining host defense in elderly individuals could thus pave the way to provide new opportunities and approaches for the treatment of severe COVID‐19.